SAB Biotherapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-06-01
- Employees
- 57
- Market Cap
- -
- Website
- http://www.sab.bio
A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo
Phase 1
Recruiting
- Conditions
- PHA1A
- Interventions
- Drug: Single Ascending Dose of SAB-176Drug: Single Ascending Dose of Placebo
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- SAb Biotherapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06435936
- Locations
- 🇺🇸
Naval Medical Research Command (NMRC), Bethesda, Maryland, United States
Study of SAB-176 in Healthy Adult Participants
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- SAb Biotherapeutics, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT04850898
- Locations
- 🇬🇧
Queen Mary BioEnterprises Innovation Centre, London, United Kingdom
Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
Phase 1
Completed
- Conditions
- Influenza Type BInfluenza Type AInfluenza
- Interventions
- Other: Normal Saline
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- SAb Biotherapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04471038
- Locations
- 🇺🇸
PPD, Phase 1 Clinic, Austin, Texas, United States
Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Phase 1
Completed
- Conditions
- COVID-19SARS-CoV2
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- SAb Biotherapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04468958
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC, Wichita, Kansas, United States
🇺🇸SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸ICON Early Phase Services, San Antonio, Texas, United States
Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19
Phase 1
- Conditions
- COVID-19SARS-CoV2
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- SAb Biotherapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT04469179
- Locations
- 🇺🇸
Quantum Clinical Trials, Miami Beach, Florida, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Sanford Health, Sioux Falls, South Dakota, United States